Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ticker
AMLX right now
Market factors today
Unlock the full AMLX picture
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
AMLX stock facts
| Ticker symbol | AMLX |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $3.3B |
| CEO | Joshua Cohen |
| Employees | 136 |
| Headquarters | Cambridge, MA, US |
| IPO date | 2022-01-07 |
| Website | amylyx.com |
What you can see for AMLX on Tickr
Live AMLX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the AMLX report.
Rankings
FAQ
What is the ticker symbol for Amylyx Pharmaceuticals, Inc.?
The ticker symbol for Amylyx Pharmaceuticals, Inc. is AMLX, listed on the NASDAQ Global Select.
What is AMLX?
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under…